AI-Focused Generate Biomedicines Prices $400M IPO
By Lauren Berg · February 27, 2026, 6:39 PM EST
The CEO of Generate Biomedicines, a biotechnology firm using artificial intelligence to develop therapies for immunology and oncology, on Friday rang the Nasdaq opening bell as the company expects to raise...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login